ReviewNature reviews. Microbiology2020
The global preclinical antibacterial pipeline.
Review in Nature reviews. Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 339 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
339 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus onFrontiers in microbiology · 2025Pooled it
- A macrophage-mimetic nanocarrier co-loaded with geraniol and FK13-a1 for MRSA-induced acute lung injury.Drug delivery · 2026Article
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- In Vitro antibacterial, anti-biofilm, and virulence-modulating activity of Cinnamomum verum-mediated iron oxide nanoparticles against carbapenem-resistant uropathogenic Escherichia coli.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Bactericidal Activity of Eugenol-RichPathogens (Basel, Switzerland) · 2026Article
- Chemical Optimization of Temporin A-L Peptides: From Native Isoforms to Enhanced Antimicrobial Analogs.ChemMedChem · 2026Review
- Synergistic potential of probiotics and bacteriophages in combating multidrug-resistant microbial infections: A novel therapeutic strategy for the post-antibiotic era.New microbes and new infections · 2026Review
- Potent Antimicrobial Chloroindium(III) Phthalocyanine Sensitizer Targeting Drug-Resistant Microbes: Physicochemical, Photobiological Validation and DFT Insights.Pharmaceutics · 2026Article
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Design, synthesis, and biological evaluation of pentacyclic triterpenoids-triphenylphosphine derivatives as antibacterial agents to combat MRSA.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- [Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Beyond Urease: New Potential Enzymatic Targets inACS omega · 2026Review
- CRISPR-based gene editing for antimicrobial resistance control in human medicine.Archives of microbiology · 2026Review
- Phenotypic Resistance Profiles, Biofilm Formation, and In Vitro Carbapenem-Sparing Antimicrobial Activity in Enterobacterales Causing Acute Pyelonephritis.Microorganisms · 2026Article
- Multidrug-ResistantPolish journal of microbiology · 2026Review
- An evaluation of the US public-private Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) initiative.Health affairs scholar · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Synergistic Potential of Plant Alkaloids and Intragenic Antimicrobial Peptides in Treating Multidrug-Resistant Infectious Diseases.Antibiotics (Basel, Switzerland) · 2026Article
- Bacterial Persister Cells as Evolutionary Catalysts of Antibiotic Resistance: Mechanisms, Clinical Implications, and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
279 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable. This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not adequately addressed yet, especially development pathways to show clinical impact of non-traditional approaches. The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.